Pharmacodynamic studies evaluation of voriconazole

doi:10.12092/j.issn.1009-2501.2018.01.022

Abstract

Abstract:

Voriconazole, as a first-line antifungal treatment, has been widely used in clinics. Significant variability of voriconazole has been found and its pharmacodynamic characteristics vary in different populations. In this paper, the review and evaluation of voriconazole pharmacodynamics are presented to indicate their determined influence factors according to populations and to investigate corresponding strategy of dosage adjustment. Therapeutic drug monitoring is suggested to combine with simulations through population pharmacokinetic/phamacodynamic model to improve the accuracy of dosage adjustment.

Key words: voriconazole, invasive fungal infection, pharmacodynamics, therapeutic drug monitoring

CLC Number:

R969.1

ZHANG Chao . Pharmacodynamic studies evaluation of voriconazole[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, doi: 10.12092/j.issn.1009-2501.2018.01.022.

References

［1］Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent［J］. Clin Infect Dis, 2003, 36(5): 630-637.
［2］Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America［J］. Clin Infect Dis, 2016, 62(4): e1-50.
［3］Patterson TF, Thompson GR, Denning DW, et al. Practice guideline for the management of aspergillosis: 2016 update by the infectious diseases society of America［J］. Clin Infect Dis, 2016, 63(4): e1-60.
［4］李方方, 徐燕丽, 张秀群, 等. 伏立康唑预防侵袭性真菌感染有效性及安全性的荟萃分析［J］. 中国感染与化疗杂志, 2012, 12(6): 453-458.
［5］Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation［J］. Blood, 2010, 116(24):5111-5118.
［6］Dolton MJ, Mikus G, Weiss J, et al. Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing［J］. J Antimicrob Chemother, 2014, 69(6): 1633-1641.
［7］Zembles TN, Thompson NE, Havens PL, et al. An optimized voriconazole dosing strategy to achieve therapeutic serum concentrations in children younger than 2 years old［J］. Pharmacotherapy,2016, 36(10): 1102-1108.
［8］Smeeken SP, Van De Veerdonk FL, Kullberg BJ, et al. Genetic susceptibility to Candida infections［J］. EMBO Mol Med, 2013, 5(6):805-813.
［9］Wojtowica A, Bochud PY. Host genetics of invasive Aspergillus and Candida infections［J］. Semin Immunopathol, 2015, 37(2):173-186.
［10］Pascual A, Csajka C, Buclin T, et al. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections［J］. Clin Infect Dis, 2012, 55(3):381-390
［11］Karthaus M, Lehrnbecher T, Lipp HP, et al. Prospective, observational study of voriconazole therapeutic drug mornitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity［J］. Antimicrob Agents Chemother, 2012, 56(5):2371-2377.
［12］Wang T, Xie J, Wang Y, et al. Pharmacokinetic and pharmacodynamic properties of oral voriconazole in patients with invasive fungal infections［J］. Pharmacotherapy, 2015, 35(9):797-804.
［13］Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration［J］. Antimicrob Agents Chemother, 2004, 48(6):2166-2172.
［14］Neely M, Margol A, Fu X, et al. Achieving target voriconazole concentrations more accurately in children and adolescents［J］. Antimicrob Agents Chemother, 2015, 59(6):3090-3097.
［15］郭一萌, 安琳娜, 陈恳, 等.伏立康唑在不同年龄段使用中安全性和有效性以及药代动力学差异的系统评价［J］.中国临床药理学杂志, 2016, 32(3): 261-263.
［16］ Doby EH, Benjamin DK, Blaschke AJ, et al. Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children［J］. Pediatr Infect Dis J, 2012, 31(6):632-635.
［17］Liu P, Mould DR. Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis［J］. Antimicrob Agents Chemother, 2014, 58(8):4718-4726.
［18］Jin H, Wang T, Folcione BA, et al. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis［J］. J Antimicrob Chemother, 2016, 71(7):1772-1785.
［19］Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes［J］. Clin Infect Dis, 2008, 46(2):201-211.
［20］Soler-Palacin P, Frick MA, Martin-Nalda A, et al. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study［J］. J Antimicrob Chemother, 2012, 67(3):700-706.
［21］Upreti VV, Wahlstrom JL. Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling［J］. J Clin Pharmacol, 2016, 56(3):266-283.
［22］Pappas PG, Kauffman CA, Andes DR, et al. Executive summary: clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America ［J］. Clin Infect Dis, 2016, 62(4):409-417.
［23］Lat A, Thompson GR. Update on the optimal use of voriconazole for invasive fungal infections［J］. Infect Drug Resist, 2011, 4:43-53.

[1]	WU Yujie, ZHAO Chengcheng, XI Qing. Evaluation of tegacycline regimens in treatment of gram-negative bacterial infections with Monte Carlo simulation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1027-1033.
[2]	WU Lili, LIANG Zhi, HUANG Siyong, WANG Yan. Effect of augmented renal clearance (ARC) on the pharmacokinetics, efficacy, and safety of vancomycin in patients with infective endocarditis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1139-1145.
[3]	GU Yifei, CHU Nannan, HUANG Kai, QUE Linling, ZHANG Jisheng, XIANG Xuemei, HE Qing. Application and progress of pharmacodynamics study in bioequivalence evaluation of orally inhaled drug products [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 822-833.
[4]	ZHANG Jinhua, LIU Maobai, CAI Mingzhi, ZHENG Yingli, LAO Haiyan, XIANG Qian, DU Liping, ZHU Zhu, DONG Jing, ZUO Xiaocong, LI Xingang, SHANG Dewei, CHEN Bing, YE Yanrong, WANG Yuzhu, GAO Jianjun, ZHANG Jian, CHEN Wansheng, XIE Haitang, JIAO Zheng. Model informed precision dosing of warfarin: China expert consensus report (2022 version) [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1201-1212.
[5]	HE Jie, LIU Dongxue, ZHONG Lingjun, SHAO Hua, HU Linlin. Establishment of a limited sampling strategy to estimate micafungin exposure in critically ill patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1264-1271.
[6]	XU Liying, ZHANG Gaosong, HUANG Xiaomin, HUANG Jihan, WANG Shuhua. Clinical efficacy and modeling evaluation of He-wei-zhi-xie capsules in treating diarrhea patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 47-55.
[7]	PENG Min, HUANG Panhao, DENG Yinhua, LIU Wen, LI Wei, YU Zhen, XIA Qing, XIE Yueliang. Analysis of influence factors of voriconazole trough concentration in patients with hematopoietic stem cell transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 640-646.
[8]	ZHANG Siliang, HU Linlin, SHAO Hua, CHEN Xijing. Research progress on the influence of sex differences on the action of psychotropic drugs#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 324-331.
[9]	JIAO Zheng, LI Xingang, SHANG Dewei, DONG Jing, ZUO Xiaocong, CHEN Bing, LIU Jianmin, PAN Yan, ZHOU Tianyan, ZHANG Jing, LIU Dongyang, LI Lujin, FANG Yi, MA Guangli, DING Junjie, ZHAO Wei, CHEN Rui, XIANG Xiaoqiang, WANG Yuzhu, GAO Jianjun, XIE Haitang, HU Pei, ZHENG Qingshan. Model informed precision dosing: China expert consensus report [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1215-1228.
[10]	LI Wenchao, BAI Xiangrong, LI Xiaoling, JIANG Dechun. Population pharmacokinetics/pharmacodynamics of tigecycline in the treatment of different infectious diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1265-1272.
[11]	XIANG Rongfeng, SUN Fengjun, XIONG Lirong, YU Mingjie, DAI Qing, CHEN Yongchuan. Pharmacokinetics and pharmacodynamics of (S)-pantoprazole sodium enteric-coated tablets in healthy subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 903-909.
[12]	GUO Mingxing, GUO Heng, SHEN Su, SUN Liying, CUI Xiangli. Retrospective analysis of voriconazole in the monitoring of therapeutic drugs in patients with liver dysfunction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 757-763.
[13]	ZHANG Lu, LIN Liangmo, LIU Keke, HUANG Yamin, HUANG Xingxing, YANG Yongyu, XIAO Jian. Therapeutic drug monitoring and pharmacokinetics of new coronavirus pneumonia antiviral drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 566-575.
[14]	LI Jian, YANG Jinbo, WANG Yuzhu. Applications of model-informed drug development (MIDD) on new drug research and development [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 1-8.
[15]	LIU Simin, CAI Jun, LI Huixin, YANG Li, ZHAO Yan, ZHANG Jinping. Research progress in population pharmacokinetics of voriconazole in adults [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1015-1023.